-
甲状腺功能亢进症(甲亢)以Graves病最为多见, 它在我国人群中的发病率约为1.2%[1]。Graves病是一种以甲状腺激素分泌异常增多为主要特征的器官特异性自身免疫性疾病, 其发生是遗传和环境因素共同作用的结果[2]。Graves病的主要治疗方法为抗甲状腺药物(antithyroid drugs, ATD)和131I治疗。在发达国家, 采取131I治疗的Graves病患者占有很大的比例。调查显示, 美国临床医师建议69%的典型Graves病患者选择131I进行治疗; 而在欧洲和日本, 这一比例也分别达到22%和11%[3]。近年来, 我国应用131I治疗的Graves病患者呈增多趋势[4], 其疗效也越来越得到学界专家的肯定[5]。众所周知, 由于Graves病本身可能存在着多种合并症和并发症, 或由于临床治疗的需要, 大多数情况下, 在131I治疗期间常常需要联合应用其他药物。而合用其他药物可能会对131I的疗效产生一定的影响。因此, 本文就近年来文献中报道的不同药物对131I治疗Graves病疗效产生的影响予以分类综述。
不同药物影响Graves病131I治疗效果的研究进展
Advance of study on the influence of different drugs on the efficacy of 131I treatment for Graves' disease
-
摘要: Graves病在甲状腺功能亢进症中最为多见,131I治疗是Graves病的主要治疗方法之一,其近年来在我国的应用呈增多趋势。在131I治疗期间,联合应用其他药物可能会影响131I的疗效。该文就近年来报道的各种药物,如抗甲状腺药物、糖皮质激素、烟酸、碳酸锂及呋塞米等对131I治疗Graves病产生的影响予以分类综述。Abstract: Graves'disease is the most common cause of hyperthyroidism. 131I treatment is one main treatment method for Graves'disease, and being used on an increasing scale in China recently.During the peritherapeutic period, however, the application of other drugs may affect the efficacy of 13I treatment.In this review, the advances of study were summarized on the influence of different drugs on the efficacy of 13I treatment in recent years.
-
Key words:
- Gravesdisease /
- Iodineradioisotopes /
- Brachytherapy /
- Antithyroidagents /
- Glucocorticoids
-
[1] 陆再英, 钟南山. 内科学. 7版. 北京: 人民卫生出版社, 2008: 712-721.
[2] Brent GA. Clinical practice. Graves'disease. N Engl J Med, 2008, 358(24): 2594-2605. doi: 10.1056/NEJMcp0801880 [3] Wartofsky L, Glinoer D, Solomon B, et al. Differences and similarities in the diagnosis and treatment of Graves'disease in Europe, Japan, and the United States. Thyroid, 1991, 1(2): 129-135. doi: 10.1089/thy.1991.1.129 [4] 蒋宁一, 匡安仁, 谭建, 等. 131I治疗Graves甲亢专家共识(2010年). 中华核医学杂志, 2010, 30(5): 346-351.
[5] 中华医学会内分泌学会《中国甲状腺疾病诊治指南》编写组. 中国甲状腺疾病诊治指南——甲状腺功能亢进症. 中华内科杂志, 2007, 46(10): 876-882. doi: 10.3760/j.issn:0578-1426.2007.10.035
[6] Oszukowska L, Knapska-Kucharska M, Makarewicz J, et al. The influence of thiamazole, lithium carbonate, orprednisone administration on the efficacy of radioiodine treatment(131I)in hyperthyroid patients. Endokrynol Pol, 2010, 61(1): 56-61. [7] BonnemaSJ, BennedbaekFN, VejeA, etal. Continuous methimazole therapy and its effect on the cure rate of hyperthyroidism using radioactive iodine: an evaluation by a randomized trial. J Clin Endocrinol Metab, 2006, 91(8): 2946-2951. doi: 10.1210/jc.2006-0226 [8] Dunkelmann S, Kuenstner H, Nabavi E, et al. Change in the intrathyroidal kinetics of radioiodine under continued and discontinued antithyroid medication in Graves'disease. Eur J Nucl Med Mol Imaging, 2007, 34(2): 228-236. doi: 10.1007/s00259-006-0234-z [9] Kung AW, Yau CC, Cheng AC. The action of methimazole and L-thyroxine in radioiodine therapy: a prospective study on the incidence of hypothyroidism. Thyroid, 1995, 5(1): 7-12. doi: 10.1089/thy.1995.5.7 [10] Kahmann C, Wunderlich G, Freudenberg R, et al. Radioprotection of thyroid cells mediated by methimazole. Int J Radiat Biol, 2010, 86(10): 811-816. doi: 10.3109/09553002.2010.488276 [11] Walter MA, Schindler C, Christ-Crain M, et al. Different strategies to overcome the effect of carbimazole on high-and low-dose radioiodine therapy: results from continuous dose-effect models. Eur J Clin Invest, 2009, 39(1): 51-57. doi: 10.1111/j.1365-2362.2008.02061.x [12] de Souza MV, Buescu A, Vaisman M, et al. The effect of propylthiouracil on the efficacy of radioiodine(I-131)therapy in graves hyperthyroidism. Arq Bras Endocrinol Metabol, 2006, 50(6): 1088-1095. doi: 10.1590/S0004-27302006000600016 [13] Walter MA, Briel M, Christ-Crain M, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and metaanalysis of randomised controlled trials. BMJ, 2007, 334(7592): 514. doi: 10.1136/bmj.39114.670150.BE [14] Sabri O, Zimny M, Schulz G, et al. Success rate of radioiodine therapy in Graves'disease: the influence of thyrostatic medication. J Clin Endocrinol Metab, 1999, 84(4): 1229-1233. [15] Lind P. Strategies of radioiodine therapy for Graves'disease. Eur J Nucl Med Mol Imaging, 2002, 29(Suppl 2): S453-S457. [16] Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves'orbitopathy(EUGOGO)on management of GO. Eur J Endocrinol, 2008, 158(3): 273-285. doi: 10.1530/EJE-07-0666 [17] Jensen BE, Bonnema SJ, Hegedüs L. Glucocorticoids do not influence the effect of radioiodine therapy in Graves'disease. Eur J Endocrinol, 2005, 153(1): 15-21. doi: 10.1530/eje.1.01924 [18] Hautzel H, Pisar E, Yazdan-Doust N, et al. Qualitative and quantitative impact of protective glucocorticoid therapy on the effective131I half-life in radioiodine therapy for Graves disease. J Nucl Med, 2010, 51(12): 1917-1922. doi: 10.2967/jnumed.110.080473 [19] Salvatore D, Fenzi G. Do glucocorticoids affect outcome in Graves'disease following radioiodine therapy?. Nat Clin Pract Endocrinol Metab, 2006, 2(4): 194-195. doi: 10.1038/ncpendmet0163 [20] Agote Robertson M, Finochietto P, Gamba CA, et al. Nicotinamide increases thyroid radiosensitivity by stimulating nitric oxide synthase expression and the generation of organic peroxides. Horm Metab Res, 2006, 38(1): 12-15. doi: 10.1055/s-2006-924966 [21] Agote M, Viaggi M, Kreimann E, et al. Influence of nicotinamide on the radiosensitivity of normal and goitrous thyroid in the rat. Thyroid, 2001, 11(11): 1003-1007. doi: 10.1089/105072501753271671 [22] Mojsak MN, Rogowski F. The usefulness of nicotinamide in radioiodine therapy in patients with toxic and nontoxic large goitres. Pol Merkur Lekarski, 2010, 29(169): 54-57. [23] Bogazzi F, Bartalena L, Brogioni S, et al. Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves'hyperthyroidism. J Clin Endocrinol Metab, 1999, 84(2): 499-503. [24] Bal CS, Kumar A, Pandey RM. A randomized controlled trial to evaluate the adjuvant effect of lithium on radioiodine treatment of hyperthyroidism. Thyroid, 2002, 12(5): 399-405. doi: 10.1089/105072502760043486 [25] Dunkelmann S, Künstner H, Nabavi E, et al. Lithium as an adjunct to radioiodine therapy in Graves'disease for prolonging the intrathyroidal effective half-life of radioiodine. Useful or not? Nuklearmedizin, 2006, 45(5): 213-218. [26] Bogazzi F, Bartalena L, Pinchera A, et al. Adjuvant effect of lithium on radioiodine treatment of hyperthyroidism. Thyroid, 2002, 12(12): 1153-1154. doi: 10.1089/105072502321085298 [27] Matovic MD, Jankovic SM, Jeremic M, et al. Unexpected effect of furosemide on radioiodine urinary excretion in patients with differentiated thyroid carcinomas treated with iodine 131. Thyroid, 2009, 19(8): 843-848. doi: 10.1089/thy.2008.0400 [28] Matovic MD, Jankovic SM, Jeremic M, et al. Effect of furosemide on radioiodine-131 retention in mice thyroid gland. Hell J Nucl Med, 2009, 12(2): 129-131.
计量
- 文章访问数: 1788
- HTML全文浏览量: 541
- PDF下载量: 2